Role of FKBP5 and its genetic mutations in stress-induced psychiatric disorders: an opportunity for drug discovery
Frontiers in Psychiatry · 16.06.2023 · 14
DOI: 10.3389/fpsyt.2023.1182345 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Psychiatry, online erschienen am 16.06.2023. Verfasst von Mahdi Malekpour und 7 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 214 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Stress-induced mental health disorders are affecting many people around the world. However, effective drug therapy for curing psychiatric diseases does not occur sufficiently. Many neurotransmitters, hormones, and mechanisms are essential in regulating the body's stress response. One of the most critical components of the stress response system is the hypothalamus-pituitary-adrenal (HPA) axis. The FKBP prolyl isomerase 51 (FKBP51) protein is one of the main negative regulators of the HPA axis. FKBP51 negatively regulates the cortisol effects (the end product of the HPA axis) by inhibiting the interaction between glucocorticoid receptors (GRs) and cortisol, causing reduced transcription of downstream cortisol molecules. By regulating cortisol effects, the FKBP51 protein can indirectly regulate the sensitivity of the HPA axis to stressors. Previous studies have indicated the influence of FKBP5 gene mutations and epigenetic changes in different psychiatric diseases and drug responses and recommended the FKBP51 protein as a drug target and a biomarker for psychological disorders. In this review, we attempted to discuss the effects of the FKBP5 gene, its mutations on different psychiatric diseases, and drugs affecting the FKBP5 gene.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.
- Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Zitieren
APA
Malekpour, M., Shekouh, D., Safavinia, M. E., Shiralipour, S., Jalouli, M., Mortezanejad, S., Azarpira, N., & Ebrahimi, N. D. (2023). Role of FKBP5 and its genetic mutations in stress-induced psychiatric disorders: an opportunity for drug discovery. Frontiers in Psychiatry, 14. https://doi.org/10.3389/fpsyt.2023.1182345
Vancouver
Malekpour M, Shekouh D, Safavinia ME, Shiralipour S, Jalouli M, Mortezanejad S, et al. Role of FKBP5 and its genetic mutations in stress-induced psychiatric disorders: an opportunity for drug discovery. Frontiers in Psychiatry. 2023;14. doi:10.3389/fpsyt.2023.1182345
BibTeX
@article{Malekpour2023,
author = {Malekpour, Mahdi and Shekouh, Dorsa and Safavinia, Mohammad Ebrahim and Shiralipour, Shadi and Jalouli, Maryam and Mortezanejad, Sahar and Azarpira, Negar and Ebrahimi, Niloofar Dehdari},
title = {Role of FKBP5 and its genetic mutations in stress-induced psychiatric disorders: an opportunity for drug discovery},
journal = {Frontiers in Psychiatry},
year = {2023},
volume = {14},
doi = {10.3389/fpsyt.2023.1182345}
}
EUVIMED